MRI major and ancillary features of LI-RADS for diagnosis of pediatric malignant liver tumors
摘要
To evaluate LI-RADS major and ancillary features for MRI-based diagnosis of pediatric malignant liver tumors.
Materials and methodsThis single-center retrospective study enrolled pediatric patients who underwent contrast-enhanced liver MRI for focal liver lesions from January 2010–February 2023. Three readers independently performed imaging analysis based on LI-RADS v2018. The reference standard was a pathological diagnosis or stability/regression for over one year on follow-up. Estimation of diagnostic accuracy and multivariable logistic regression were conducted to identify LI-RADS features associated with malignant hepatocellular tumors and hepatic malignancy in general.
ResultsOf the 102 patients (median age [interquartile range], 4.5 [0.6–14.0] years; boys:girls, 54:48), 58.8% (60/102) had malignant liver tumors and 49.0% (50/102) had malignant hepatocellular tumors. The sensitivity and specificity of major features for diagnosis of malignant hepatocellular tumors were as follows: nonrim arterial enhancement, 73.4% and 39.6%; enhancing capsule, 56.7% and 92.0%; nonperipheral washout, 70.1% and 94.2%. Nonperipheral washout (sensitivity, 70.1%; specificity, 94.2%; adjusted OR, 34.5; p < 0.001), restricted diffusion (sensitivity, 97.9%; specificity, 53.8%; adjusted OR, 72.3; p = 0.001), and fat-in-mass (sensitivity, 29.0%; specificity, 93.0%; adjusted OR, 4.3; p = 0.01) were associated with malignant hepatocellular tumors, while nonperipheral washout (sensitivity, 58.7%; specificity, 94.5%; adjusted OR, 12.5; p < 0.001), restricted diffusion (sensitivity, 97.1%; specificity, 65.8%; adjusted OR, 31.1; p < 0.001), and mosaic architecture (sensitivity, 79.5%; specificity, 90.0%; adjusted OR, 20.4; p < 0.001) were associated with hepatic malignancy in general.
ConclusionRestricted diffusion was a sensitive MRI LI-RADS feature, while nonperipheral washout and mosaic architecture were specific features for diagnosing pediatric malignant liver tumors.
Key Points